Table 1

Patient characteristics and evaluation of potential predictors for long term survival

All patients (n = 120)Long term survivors
(n =58)
Deceased patients
(n = 62)
p Value
Recipient related factors
Age at transplant (years)42.3 (11.8)42.1 (11.5)42.5 (11.6)0.8
Sex
 Male98 (81.7%)49 (84.5%)49 (79%)0.4
 Female22 (18.3%)9 (15.5%)13 (21%)
Cause of heart failure
 DCM69 (57.5%)36 (62.1%)33 (53.2%)0.2
 CAD42 (35%)16 (27.6%)26 (41.9%)
 Others9 (7%)6 (10.3%)3 (4.8%)
Cholesterol at year 1 (mmol/l)6.7 (2.0)7.0 (2.3)6.4 (1.6)0.1
Triglycerides at year 1 (mmol/l)2.6 (1.8)2.6 (1.9)2.5 (1.4)0.8
Donor related factors
Donor age25.6 (8.7)23.9 (8.8)26.9 (8.4)0.08
Donor sex
 Male83 (69.2%)38 (65.5%)45 (72.6%)0.9
 Female27 (22.5%)12 (20.7%)15 (24.2%)
CMV mismatch (mismatch/non- mismatch)25/409/1716/230.4
Ischaemic time (min)137.6 (43.1)137.2 (42.8)138 (43)0.9
HLA mismatch (47 missing)4.6 (0.9)4.6 (1.0)4.6 (0.9)0.8
Drug treatment
ATG treatment9946530.7
Mean dose of cyclosporin (mg/day)327.8 (83.0)318.7 (81.8)338.1 (84.0)0.2
Mean dose of azathioprine (mg/day)99.8 (30.4)102 (25.5)97 (35.2)0.4
Mean dose of prednisolone at year 1 (mg/day)10.9 (3.4)10.7 (3.7)10.9 (3.0)0.8
Number of antihypertensive drugs at year 1 1.2 (0.9)1.0 (0.9)0.7
  • Data are expressed as mean value (SD) and n (%). Groups were compared by unpaired two tailed t test for independent values. Non-continuous variables were assessed by χ2 analysis. p Values < 0.05 were considered statistically significant.

  • ATG, antithymocyte globulin; CAD, coronary artery disease; DCM, dilated cardiomyopathy.